Injectable Fillers for Head and Neck Conditions - (0511) — MM 0511 | CIGNA Coverage Update

TL;DR: Cigna Healthcare modified MM 0511, its injectable fillers for head and neck conditions coverage policy, effective September 26, 2025. Here's what billing teams need to do.

Cigna Healthcare updated MM 0511 — the Cigna injectable fillers coverage policy governing vocal cord paralysis treatment, velopharyngeal insufficiency, and facial lipodystrophy syndrome. The change draws a hard line between covered procedures (laryngoscopy-based vocal cord injections under CPT 31513, 31570, 31571, 31573, and 31574, plus fat grafting codes 15769 and 15773) and codes the payer considers not medically necessary (subcutaneous filler codes 11950–11954 and bilateral fat grafting CPT 15774). If your billing team handles otolaryngology, laryngology, or HIV-related lipodystrophy cases, this update directly affects your reimbursement and claim denial risk.

Quick-Reference Table

Cigna Injectable Fillers Coverage Criteria and Medical Necessity Requirements 2025

The core of this Cigna injectable fillers coverage policy is a three-condition framework. Cigna covers injectable and augmentation procedures for vocal cord paralysis, velopharyngeal insufficiency, and facial lipodystrophy syndrome — but only when the claim maps to the right procedure codes and meets the medical necessity criteria in the applicable coverage position.

Vocal cord paralysis is the highest-stakes category here. Cigna covers direct and indirect laryngoscopy with vocal cord injection under CPT 31513 (indirect), 31570 (direct), and 31571 (direct, with operating microscope or telescope). Flexible laryngoscopy codes 31573 (therapeutic injection, e.g., chemodenervation or corticosteroid) and 31574 (injection for augmentation, unilateral) are also covered when criteria are met. On the supply side, HCPCS C1878 (synthetic implantable material for vocal cord medialization) and L8607 (injectable bulking agent for vocal cord medialization, 0.1 ml) both sit in the covered column.

Velopharyngeal insufficiency — the failure of the soft palate to fully close against the pharynx — gets covered under J3590 (unclassified biologics) when the clinical picture supports it. This is the code to watch. J3590 is a catch-all, and Cigna's use of it here means your documentation has to be airtight. The payer needs to see why a named injectable wasn't billed — and why J3590 was the right call.

Facial lipodystrophy syndrome, most commonly seen in HIV patients on antiretroviral therapy, has two relevant codes. G0429 covers dermal filler injections for lipodystrophy syndrome — specifically called out as including HIV antiretroviral-related causes. Q2026 (Radiesse, 0.1 ml) and Q2028 (Sculptra, 0.5 mg) are both covered under this policy when criteria are met.

Autologous fat grafting via liposuction to the face and related areas (CPT 15773) and direct excision-based soft tissue grafting (CPT 15769) are covered when selection criteria are satisfied. These are the medically necessary pathways for volume restoration — not the subcutaneous filler codes.

Prior authorization requirements are not explicitly detailed in the published MM 0511 summary. That doesn't mean prior auth is off the table. For any procedure in this policy, check Cigna's prior authorization list before scheduling. Vocal cord augmentation and lipodystrophy treatment are the types of cases that routinely trigger utilization review.

Cigna Injectable Fillers Exclusions and Non-Covered Indications

This is where the policy gets expensive if your team misses it.

CPT codes 11950, 11951, 11952, and 11954 — the subcutaneous injection of filling material codes (collagen and similar agents, spanning 1 cc up to over 10 cc) — are explicitly designated not medically necessary under MM 0511. Full stop. These codes might seem like a natural fit for volume augmentation in the head and neck, but Cigna is saying they are not the right codes for the covered conditions in this policy.

CPT 15774 — autologous fat grafting by liposuction technique, bilateral — is also not medically necessary under this policy. Note the contrast with 15773, which covers the same procedure unilaterally and is covered when criteria are met. Billing 15774 instead of 15773 on a Cigna claim for a lipodystrophy patient is a direct path to a claim denial.

The real issue here is code selection at the point of charge capture. A coder who sees "fat grafting, face" and defaults to 15774 without checking laterality and coverage status will generate denials on every one of these cases. That's a fixable workflow problem — but only if your team knows about it before September 26, 2025.

Coverage Indications at a Glance

Cigna Injectable Fillers Billing Guidelines and Action Items 2025

These are the steps your billing and coding team should complete before September 26, 2025.

1. Pull every active charge capture template that includes CPT 11950, 11951, 11952, or 11954.
Flag them for review. These codes are not medically necessary under MM 0511 for any of the three covered conditions. If your practice uses them for non-head-and-neck indications, confirm those claims won't accidentally route under this policy. If they're being used for vocal cord or lipodystrophy cases, replace them with the appropriate covered codes immediately.

2. Audit CPT 15773 vs. 15774 usage for Cigna lipodystrophy and facial augmentation cases.
The distinction is unilateral vs. bilateral. CPT 15773 is covered; 15774 is not. Review the last 12 months of claims to see if 15774 was billed on Cigna patients for these indications. If it was, assess your exposure and talk to your compliance officer about whether corrections are warranted before the effective date.

3. Update your coding guidelines for flexible laryngoscopy with injection.
CPT 31573 and 31574 are both in the covered column — but 31574 is unilateral. Bilateral augmentation injections via flexible laryngoscopy need separate billing guidance. Make sure your coders understand what triggers each code and what documentation Cigna will need to support medical necessity.

4. Standardize your documentation templates for J3590 claims.
J3590 is an unclassified biologic code. Cigna covers it for velopharyngeal insufficiency under MM 0511, but unclassified codes almost always require additional documentation — a letter of medical necessity, the specific product name, dosage, and clinical rationale. Build those elements into your pre-authorization and clinical documentation workflow now.

5. Confirm prior authorization protocols for Q2026 (Radiesse) and Q2028 (Sculptra) claims.
These are named injectable products with specific HCPCS codes. Cigna's coverage position is that they're medically necessary when criteria are met for lipodystrophy — but that doesn't mean prior auth is waived. Check Cigna's current prior authorization list for these codes. If your infectious disease or plastic surgery teams are billing these for HIV lipodystrophy patients, they need to know what documentation Cigna expects before the filler is administered.

6. Brief your front-end team on G0429 and the lipodystrophy diagnosis link.
G0429 is specifically for facial lipodystrophy syndrome, including HIV antiretroviral-related cases. The diagnosis on the claim has to support that indication. A generic "facial volume loss" diagnosis without the lipodystrophy connection will generate a denial. Make sure your charge capture for HIV clinic or infectious disease referrals captures the right diagnosis codes to pair with G0429.

If you're unsure how this policy interacts with your specific payer mix or patient population, loop in your compliance officer or billing consultant before September 26, 2025.

CPT, HCPCS, and ICD-10 Codes for Injectable Fillers Under MM 0511

Covered CPT Codes (When Selection Criteria Are Met)

Covered HCPCS Codes (When Selection Criteria Are Met)

Not Covered / Non-Medically Necessary Codes

No ICD-10-CM diagnosis codes are specified in the published MM 0511 policy data.